1. Home
  2. HIPO vs MNKD Comparison

HIPO vs MNKD Comparison

Compare HIPO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hippo Holdings Inc.

HIPO

Hippo Holdings Inc.

HOLD

Current Price

$26.25

Market Cap

676.8M

Sector

Finance

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$2.83

Market Cap

793.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIPO
MNKD
Founded
2015
1991
Country
United States
United States
Employees
540
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
676.8M
793.6M
IPO Year
N/A
2004

Fundamental Metrics

Financial Performance
Metric
HIPO
MNKD
Price
$26.25
$2.83
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$38.67
$8.69
AVG Volume (30 Days)
71.6K
3.3M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.02
Revenue
N/A
$348,966,000.00
Revenue This Year
$28.28
$35.81
Revenue Next Year
$22.33
$11.89
P/E Ratio
$7.64
$137.75
Revenue Growth
N/A
22.23
52 Week Low
$19.92
$2.23
52 Week High
$38.98
$6.51

Technical Indicators

Market Signals
Indicator
HIPO
MNKD
Relative Strength Index (RSI) 40.54 51.93
Support Level $24.85 $2.52
Resistance Level $27.12 $2.98
Average True Range (ATR) 0.93 0.13
MACD -0.05 0.05
Stochastic Oscillator 40.48 63.53

Price Performance

Historical Comparison
HIPO
MNKD

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: